Antibody Information
General Information of This Antibody
| Antibody ID | ANI0QDIPL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Z4681A |
|||||
| Synonyms |
Z4681A
Click to Show/Hide
|
|||||
| Antigen Name | Myeloid cell surface antigen CD33 (CD33) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IMGN779 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have relapsed/refractory AML (dose escalation) or be unsuitable for induction therapy (expansion), excluding those with acute promyelocytic leukemia, active CNS involvement, prior IMGN779 exposure, or recent anticancer therapy (within 14 days/five half-lives), as well as pregnant/breastfeeding women. Hydroxyurea or leukapheresis is permitted for hyperleukocytosis control.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02674763 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
|
||||
| Primary Endpoint |
The primary objective is to determine the maximum tolerated dose (MTD) of IMGN779 in patients with relapsed or refractory acute myeloid leukemia (AML) over a 28-day period during the dose escalation phase.
|
||||
| Other Endpoint |
Secondary endpoints include evaluating treatment-emergent adverse events, objective response rate (ORR), pharmacokinetic parameters (Cmax, AUC, t½), and immunogenicity (anti-drug antibodies) over a 12-month observation period to assess safety, efficacy, and drug exposure characteristics.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
IMGN779 (0.5 mg/kg, a single dose) induces efficient tumor cell killing in cell line-derived models of MV4-11 cells with CD33 expression with high expression.
|
||||
| In Vivo Model | MV4-11 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
EOL-1 tumor-bearing mice received a single intravenous bolus administration of vehicle, IMGN779, or Ab-DGN462, with each conjugate molecule dosed at approximately 1.5 mg/kg ADC by antibody concentration (i.e., 10 or 30 ug/kg linked IGN).
|
||||
| In Vivo Model | EOL-1 CDX model | ||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
References